Bevacizumab in Advanced Adenocarcinoma of the Pancreas. Original Policy Date
|
|
- Marion Davis
- 5 years ago
- Views:
Transcription
1 Bevacizumab in Advanced Adenocarcinoma of the Pancreas Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage. Medical technology is constantly changing, and we reserve the right to review and update our policies periodically. Description Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor-a (VEGF-A). Vascular endothelial growth factors (VEGFs) and their receptors (VEGF-Rs) contribute to tumor growth and metastasis by promoting angiogenesis. This policy examines the available evidence for the off-label use of bevacizumab in patients with advanced adenocarcinoma of the pancreas. In the U.S., pancreatic adenocarcinoma is the tenth most common cancer in men and the fourth leading cause of cancer deaths in men and women. Only 7% of cases are detected at an early stage, and more than 90% of patients develop metastases. The 1-year survival rate is 25%; the 5-year survival rate is 6% overall, and 22% for those diagnosed early with only local disease. For patients with advanced, unresectable disease, the standard of care is gemcitabine. Gemcitabine is approved by the U.S. Food and Drug Administration (FDA) as a single-agent first-line treatment for patients with locally advanced (stage II or stage III when surgery is not an option) or metastatic (stage IV) adenocarcinoma of the pancreas, including patients previously treated with 5-fluorouracil. Gemcitabine is sometimes given as part of combination therapy with another agent, such as erlotinib, which is approved by the FDA for first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. Vascular endothelial growth factors (VEGFs) and their receptors (VEGF-Rs) contribute to tumor growth and metastasis by promoting angiogenesis, the growth of new vasculature. (1-4) Without angiogenesis, nutrients, oxygen and other essential molecules reach malignant cells only by passive diffusion from pre-existing blood vessels, which would limit most tumors to diameters of several millimeters. Certain normal physiologic processes (e.g., embryonic development, menstruation, wound healing) require angiogenesis, and some non-cancer pathologic processes are linked to angiogenesis (e.g., macular degeneration, atherosclerosis, psoriasis). (5) Regulatory Status
2 Bevacizumab for the treatment of advanced pancreatic adenocarcinoma is not a U.S. Food and Drug Administration (FDA)-labeled indication. Policy Bevacizumab is considered investigational for treatment of advanced adenocarcinoma of the pancreas. Policy Guidelines The HCPCS code for bevacizumab is: J9035: Injection, bevacizumab, 10 mg. Rationale This policy is adapted from a 2009 TEC Assessment. (6) The objective of the Assessment was to evaluate the use of bevacizumab in advanced adenocarcinoma of the pancreas to identify any incremental benefit of using bevacizumab in these patients, taking into account potential increases in survival and quality of life, as well as the effects of adverse events caused by the treatment. This policy has been updated annually, with the most recent MEDLINE literature search through August Because vascular endothelial growth factor (VEGF) appears to play a role in pancreatic cancer, bevacizumab was considered a promising therapy, and the results of 2 Phase II trials seemed to indicate potential benefit as well. (7, 8) Approximately 89 93% of pancreatic cancer patients have a VEGF mutation, which is associated with early recurrence after surgery, liver metastases, and poor prognosis. Finding VEGF in tumors is also correlated with tumor size. (9) Five studies were identified for review as part of the Assessment that tested the use of bevacizumab in patients with advanced adenocarcinoma. These studies consisted of 2 Phase III trials, 2 Phase II, and 1 Phase I trial. In all trials, bevacizumab was added to gemcitabine, the latter which is considered the current standard of care. Some trials also included other agents as well, including cisplatin and erlotinib. The 2 Phase III studies, one by Kindler and colleagues (10) and the second by van Cutsem and colleagues, (11) provided the strongest evidence because of their design. Neither study demonstrated that the addition of bevacizumab resulted in a statistically significant difference in the primary outcome of overall survival (OS). For the secondary outcome of progression-free survival (PFS), the van Cutsem et al. study appeared to show benefit, while the Kindler et al. study did not. Kindler and colleagues randomly assigned 590 patients with advanced cancer (local or metastatic) to gemcitabine with or without bevacizumab. (12) The trial was stopped early when it was determined that the combination of gemcitabine plus bevacizumab could not achieve longer survival than the gemcitabine-alone arm of the trial. Van Cutsem and colleagues randomly assigned 607 patients with metastatic adenocarcinoma of the pancreas to gemcitabine plus erlotinib, with or without bevacizumab. (11) There was no
3 statistically significant difference between the 2 groups in the primary outcome of OS. The median OS was 7.1 months for the treatment group and 6.0 months for the control group (hazard ratio [HR]: 0.89; 95% confidence interval [CI]: %; p=0.21). The study reported a statistically significant difference in PFS of 4.6 months in the treatment arm and 3.6 months in the control group (HR: 0.73; 95% CI: %; p=0.0002). Although this secondary outcome was significant, there were few details given regarding the methods used to assess PFS, which may be subject to greater measurement error than OS. It was anticipated that bevacizumab could offer benefit in advanced adenocarcinoma of the pancreas because the drug targets VEGF, which is thought to play an important role in pancreatic cancer and because of an apparently positive effect in a Phase II clinical trial. (12) Unfortunately, the results of 2 Phase III trials, one of which was stopped early because of lack of OS benefit, and the second recently released trial also showed no incremental benefit in OS. In 2009, Crane and colleagues assessed 1-year survival in a case series of patients with locallyadvanced, unresectable pancreatic cancer. (13) Overexpression of VEGF by pancreatic cancer cells may diminish the effectiveness of radiation therapy. The authors suggest that the action of bevacizumab in reducing VEGF expression may therefore improve radiation therapy outcomes. One-year OS in patients with locally-advanced disease receiving radiation and paclitaxel without VEGF inhibition was 43% in a previous study. To examine the effectiveness of the combination of bevacizumab, capecitabine, and radiation, 94 patients were recruited to detect a 15% improvement in the 1-year survival rate over the 43% seen in the previous study. Crane et al. reported a 47% survival rate (95% CI: 36% to 57%, not statistically different compared to the previous study). The authors concluded that the addition of bevacizumab does not contribute to an improved 1-year survival rate. Javle and colleagues reported the results of a single-arm study of 50 patients with metastatic pancreatic cancer treated with capecitabine, gemcitabine, and bevacizumab. (14) The primary endpoint was PFS based on radiologic measure or tumor size, and serum CA 19-9 levels, the latter a biomarker associated with pancreatic cancer burden. Secondary endpoints included OS, response rate, and toxicity. In this study, discontinuation of therapy was higher than anticipated, with 46 of 50 (92%) subjects not continuing due to death, disease progression, or adverse events. Although some radiologic response and reduction in CA 19-9 levels did occur, PFS at 1 year was 19% (95% CI: %). Overall survival at 1 year reached 35.5% (95% CI: %). The authors commented that, based on this study and previous results for bevacizumab, they have chosen not to proceed with Phase III studies. In 2010, Astsaturov and colleagues reported on a comparative trial for patients with metastatic pancreatic cancer. (15) Patients were randomly assigned to receive bevacizumab alone or in combination with docetaxel cytotoxic therapy. There was no blinding. The primary endpoint was PFS. However, at 4 months, only 2 and 3 patients were stable, respectively, and the trial was discontinued on the study-defined grounds of futility of less than 25% PFS at that time. Ko and colleagues reported partial results of an observational study of gemcitabine refractory metastatic pancreatic cancer patients treated with bevacizumab and erlotinib. (16) Recruitment stalled after publication of the relative ineffectiveness of bevacizumab in the Phase III trials previously described. Of the 36 patients followed in the study, 8 reached the primary endpoint of 6-month survival (22%). This survival rate is inferior to published rates of cytotoxic regimens.
4 Martin and colleagues investigated the safety and efficacy of bevacizumab combined with gemcitabine followed by infusional 5-fluorouracil (5-FU) in patients with advanced pancreatic cancer in a Phase 2 trial. (17) The primary endpoint was the proportion of patients with PFS at 6 months from initiation of therapy. If PFS at 6 months was equal to or greater than 41%, the regimen would be considered promising. Of the 42 patients enrolled in the study, 39 were evaluable for the primary endpoint. PFS at 6 months was 49% (95% CI: 34% to 64%). Median PFS was 5.9 months (95% CI: 3.5 to 8.1), and median OS was 7.4 months (95% CI: 4.7 to 11.2). Partial response and stable disease occurred in 30% and 45% of patients, respectively. Grade 3 to 4 toxicities included fatigue (14%), hypertension (5%), and venous thrombosis (5%). The authors concluded that the study met its primary endpoint and that further investigation of anti-vegf therapy in combination with fluoropyrimidine-based therapy is warranted in advanced pancreatic cancer. Ko and colleagues conducted a Phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for advanced pancreatic adenocarcinoma. (18) Patients with locally advanced or metastatic pancreatic adenocarcinoma, previously untreated, were randomized to bevacizumab plus cetuximab, either with (Arm A; n=30) or without (Arm B; n=31) gemcitabine. Tumor assessments were performed every 8 weeks. The primary study endpoint was progression-free survival (PFS). The median treatment duration was 9 weeks in Arm A and 8 weeks in Arm B (range: ). Patients in Arm A had median PFS and overall survival (OS) values of 3.55 months and 5.41 months, respectively, compared to 1.91 months and 4.17 months in Arm B. The study closed early due to lack of sufficient efficacy in both treatment arms. The authors concluded that the combination of cetuximab and bevacizumab did not result in promising activity with or without gemcitabine, and suggested that a strategy of dual epidermal growth factor receptor (EGFR)/VEGF inhibition in pancreatic cancer does not warrant further development. Fogelman and colleagues conducted a Phase II trial of bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer. (19) Eligible patients had stage III (n=14) or IV (n=36) pancreatic cancer and had received no prior gemcitabine. Treatment cycles were repeated every 2 weeks, and CT imaging was performed every 6 weeks. Fifty patients were enrolled: 14 had stage III disease, the remainder, stage IV. Median age was 59 years. The overall response rate was 36%; 34% demonstrated stable disease. The median PFS was 4.9 months; median survival was 11.9 months; 1 year survival was 42%. Patients with locally advanced disease lived 12.8 months; patients with metastatic disease lived 10.2 months. The authors concluded that the regimen did not meet the objective of a 14-month median survival and that the toxicity was significant. Summary Treatment of advanced adenocarcinoma of the pancreas with bevacizumab is not an FDAapproved indication. The available evidence does not clearly demonstrate that addition of bevacizumab to chemotherapy regimens for advanced adenocarcinoma of the pancreas improves the net health outcome of those patients. Therefore, bevacizumab for patients with advanced adenocarcinoma of the pancreas is considered investigational. Practice Guidelines and Position Statements National Comprehensive Cancer Network (NCCN) guidelines state that gemcitabine is recommended for pancreatic cancer patients with locally advanced or metastatic disease, and
5 studies have suggested some benefit from adding another chemotherapy agent (such as cisplatin or fluoropyrimidine). The guidelines state that the only new targeted drug for which there is evidence of a statistically significant increase in survival when combined with gemcitabine is erlotinib. (20) National Cancer Institute s Clinical Trial Database No Phase 3 trials on the use of bevacizumab in advanced pancreatic cancer were identified. Medicare National Coverage No national coverage determination. References: 1. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 2006; 63(5): Verheul HM, Pinedo HM. Inhibition of angiogenesis in cancer patients. Expert Opin Emerg Drugs 2005; 10(2): Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 2005; 6(10): Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005; 23(8): Blue Cross and Blue Shield Technology Evaluation Center (TEC). Off-label uses of bevacizumab: breast and lung cancer indications. TEC Assessments 2006; Volume 21, Tab Blue Cross and Blue Shield Technology Evaluation Center (TEC). Off-label use of bevacizumab: advanced adenocarcinoma of the pancreas. TEC Assessments 2009; Volume 24, Tab Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw 2005; 3(5): Ducreux M, Boige V, Malka D. Treatment of advanced pancreatic cancer. Semin Oncol 2007; 34(2 Suppl 1):S Borja-Cacho D, Jensen EH, Saluja AK et al. Molecular targeted therapies for pancreatic cancer. Am J Surg 2008; 196(3): Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28(22): Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27(13): Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23(31):
6 13. Crane CH, Winter K, Regine WF et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG J Clin Oncol 2009; 27(25): Javle M, Yu J, Garrett C et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 2009; 100(12): Astsaturov IA, Meropol NJ, Alpaugh RK et al. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2011; 34(1): Ko AH, Venook AP, Bergsland EK et al. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2010; 66(6): Martin LK, Li X, Kleiber B et al. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol 2012 [Epub ahead of print]. 18. Ko AH, Youssoufian H, Gurtler J et al. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs 2012; 30(4): Fogelman D, Jafari M, Varadhachary GR et al. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2011; 68(6): National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (V1.2012) Available online at: Last accessed August, Codes Number Description CPT Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug each additional hour (List separately in addition to code for primary procedure) HCPCS J9035 Injection, bevacizumab, 10 mg ICD-10-CM (effective 10/1/13) ICD-10-PCS (effective 10/1/13) Investigational for all relevant diagnoses C25.0 C25.9 Malignant neoplasm of pancreas code range ICD-10-PCS codes are only used for inpatient services. 3E03305, 3E04305, Administration, physiological systems and
7 Index Avastin, Pancreas Cancer Bevacizumab, Pancreas Cancer 3E05305, 3E06305 anatomical regions, introduction, percutaneous, antineoplastic, other antineoplastic, code by anatomical route (peripheral vein, central vein, peripheral artery, central artery)
Avastin (bevacizumab)
Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: Provider Notice Date: CLINICAL MEDICAL POLICY Portrazza (Necitumumab) MP-021-MD-WV Medical Management Original Effective Date: 06/02/2016 Annual Approval Date:
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationPolicy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.
Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate
More informationDescription of Procedure or Service. Policy. Benefits Application
Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationMP Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer
MP 2.04.56 Laboratory Testing to Allow Area Under the Curve (AUC) Targeted 5- Flourouracil (5-FU) Dosing for Patients Administered 5-FU for Cancer Medical Policy Section Medicine Issue 12:2013 Original
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationBevacizumab (Avastin)
Bevacizumab (Avastin) Policy Number: Original Effective Date: MM.04.001 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service:
More informationClinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119
Clinical Policy: (Cyramza) Reference Number: CP.PHAR.119 Effective Date: 05/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.04 Subject: Avastin Page: 1 of 8 Last Review Date: December 3, 2015 Avastin Description Avastin (bevacizumab)
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationFDA APPROVES AVASTIN FOR THE MOST COMMON TYPE OF KIDNEY CANCER
NEWS RELEASE Media Contact: Amy Berry (650) 467-6800 Advocacy Contact: Kristin Reed (650) 467-9831 Investor Contacts: Kathee Littrell (650) 225-1034 Karl Mahler 011 41 61 687 85 03 FDA APPROVES AVASTIN
More informationIs Bevacizumab (Avastin) Safe and Effective as Adjuvant Chemotherapy for Adult Patients With Stage IIIb or IV Non-Small Cell Lung Carcinoma (NSCLC)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Bevacizumab (Avastin) Safe and Effective
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationName of Policy: Bevacizumab, Avastin
Name of Policy: Bevacizumab, Avastin Policy #: 377 Latest Review Date: September 2013 Category: Pharmacology Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationThe efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-1295-2 April 2014, Vol. 13, No. 4, P169 P173 The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationUse of Vascular Endothelial Growth Factor Receptor (VEGF) Inhibitors and Other Angiogenesis Inhibitors in Oncology Patients
PHARMACY / MEDICAL POLICY 5.01.517 Use of Vascular Endothelial Growth Factor Receptor (VEGF) Inhibitors and Other Angiogenesis Inhibitors in Oncology Patients Effective Date: June 1, 2018 RELATED MEDICAL
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationBevacizumab for the treatment of recurrent advanced ovarian cancer
Bevacizumab for the treatment of recurrent advanced ovarian cancer ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/40 Page 2 This document contains errata in respect
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationName of Policy: Panitumumab, Vectibix
Name of Policy: Panitumumab, Vectibix Policy #: 369 Latest Review Date: June 2014 Category: Pharmacology Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationClinical Policy: Bevacizumab (Avastin) Reference Number: ERX.SPMN.127
Clinical Policy: (Avastin) Reference Number: ERX.SPMN.127 Effective Date: 03/14 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationWhat Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015
What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 Eileen M. O Reilly, M.D. Associate Director David M. Rubenstein Center Pancreatic Cancer Research
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationName of Policy: Cellular Immunotherapy for Prostate Cancer
Name of Policy: Cellular Immunotherapy for Prostate Cancer Policy #: 432 Latest Review Date: July 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits are payable
More informationPanel Two: Evidence for Use of Maintenance Therapy
Panel Two: Evidence for Use of Maintenance Therapy Evidence for Use of Maintenance Therapy Richard L. Schilsky University of Chicago Comprehensive Cancer Center What is maintenance therapy? The continued
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationMedia Release. Basel, 17 May 2018
Media Release Basel, 17 May 2018 Phase III IMpower150 study showed Roche s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly
More informationOphthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors
Ophthalmologic Policy UnitedHealthcare Commercial Drug Policy Vascular Endothelial Growth Factor (VEGF) Inhibitors Policy Number: 2016D0042H Effective Date: October 1, 2016 Table of Contents Page INSTRUCTIONS
More informationGemcitabine and Capecitabine for Advanced Adenocarcinoma of the Pancreas
Gemcitabine and Capecitabine for Advanced Adenocarcinoma of the Pancreas Robert D. Levin, MD Abstract Background: Chemotherapy for advanced adenocarcinoma of the pancreas may have severe toxicities including
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer October 29, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationOvarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion Syndrome. Original Policy Date
MP 4.01.11 Ovarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion Syndrome Medical Policy Section OB/Gyn/Reproduction Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationColorectal Cancer Therapy and Associated Toxicity
Colorectal Cancer Therapy and Associated Toxicity Mountain States Cancer Conference November 6, 2010 Colin D. Weekes, M.D., Ph.D Assistant Professor University of Colorado GI Cancers Are Common 2009 Estimated
More informationBevacizumab is currently licensed for the following indication relevant for this NICE review:
Roche Executive Summary Context Bevacizumab (Avastin) is a humanized (93% human) murine monoclonal antibody which binds to and neutralizes VEGF, a powerful pro-angiogenic glycoprotein produced by both
More informationGastric cancer and lung cancer impose a substantial
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non Small-Cell Lung Cancer By Loretta Fala, Medical Writer Gastric cancer and lung cancer impose a substantial
More informationDisclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer
Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,
More informationGastric cancer is the fourth
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Ramucirumab: A New Therapy for Advanced Gastric Cancer ANDREA LANDGRAF OHOLENDT, PharmD, BCOP, and JENNIFER L. ZADLO, PharmD, BCOP From The University
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationPolicy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016
Name of Policy: Tecentriq (Atezolizumab) Policy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016 Background/Definitions: As a general rule, benefits are
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationTarceva. Tarceva (erlotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Aflibercept (Zaltrap) for Metastatic Colorectal Cancer September 5, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Aflibercept (Zaltrap) for Metastatic Colorectal Cancer September 5, 2014 DISCLAIMER Not a Substitute for Professional Advice This report
More informationName of Policy: Yervoy (Ipilimumab)
Name of Policy: Yervoy (Ipilimumab) Policy #: 335 Latest Review Date: October 2013 Category: Pharmacology Policy Grade: A Background/Definitions: As a general rule, benefits are payable under Blue Cross
More informationEnd Diastolic Pneumatic Compression Boot as a Treatment of Peripheral Vascular Disease or Lymphedema. Original Policy Date
MP 2.02.12 End Diastolic Pneumatic Compression Boot as a Treatment of Peripheral Vascular Disease or Lymphedema Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationDescription Sorafenib (Nexavar) is an oral medication used to treat certain types of cancer. It works by blocking the growth of cancer cells.
Medication Policy Manual Policy No: dru134 Topic: Nexavar, sorafenib Date of Origin: March 10, 2006 Committee Approval Date: November 13, 2014 Next Review Date: November 2015 Effective Date: December 1,
More informationMedia Release. Basel, 7 May 2018
Media Release Basel, 7 May 2018 FDA grants priority review to Roche s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche
More informationPancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationTrial record 1 of 1 for: GO28341 Previous Study Return to List Next Study
1 von 5 11.12.2013 09:04 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: GO28341 Previous Study Return to List Next Study A Study of GDC-0068 in Combination With Fluoropyrimidine
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationWhere Are Anti-Angiogenic Agents Positioned Within Cancer Care Guidelines?
Introduction Additionally, other anti-angiogenic drugs, including sorafenib, sunitinib, axitinib, pazopanib, vandetanib, The development and subsequent use of drugs for treating cancer cabozantinib, and
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationClinical Policy Bulletin: Ixabepilone (Ixempra) AETNA BETTER HEALTH 12/08/2014. Aetna Better Health 2000 Market Suite Ste. 850 Philadelphia, PA 19103
Page 1 of8 Aetna Better Health 2000 Market Suite Ste. 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Clinical Policy Bulletin: Ixabepilone (Ixempra) Number: 0869 Policy Aetna considers ixabepilone (Ixempra)
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationPolicy No: dru281. Medication Policy Manual. Date of Origin: September 24, Topic: Perjeta, pertuzumab. Next Review Date: May 2015
Medication Policy Manual Topic: Perjeta, pertuzumab Committee Approval Date: May 9, 2014 Policy No: dru281 Date of Origin: September 24, 2012 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationCyramza (ramucirumab)
Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationMEDICAL POLICY. SUBJECT: ISOLATED LIMB PERFUSION and INFUSION
MEDICAL POLICY SUBJECT: ISOLATED LIMB PERFUSION and PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationHematopoietic Stem Cell Transplantation for Epithelial Ovarian Cancer
Hematopoietic Stem Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 04/22/2016 Section:
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More information